{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T22:13:53Z","timestamp":1790547233530,"version":"4.1.0"},"reference-count":268,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,17]],"date-time":"2024-01-17T00:00:00Z","timestamp":1705449600000},"content-version":"am","delay-in-days":687,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100005946","name":"Hokkaido University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005946","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.jconrel.2022.01.046","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T23:00:32Z","timestamp":1643842832000},"page":"361-378","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"special_numbering":"C","title":["Strategies for fighting pandemic virus infections: Integration of virology and drug delivery"],"prefix":"10.1016","volume":"343","author":[{"given":"Takashi","family":"Nakamura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norikazu","family":"Isoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiro","family":"Sakoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideyoshi","family":"Harashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2022.01.046_bb0005","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrmicro1208","article-title":"Influenza: lessons from past pandemics, warnings from current incidents","volume":"3","author":"Horimoto","year":"2005","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0015","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"Zhou","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0020","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41586-020-2169-0","article-title":"Identifying SARS-CoV-2-related coronaviruses in Malayan pangolins","volume":"583","author":"Lam","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0025","author":"WHO Global Influenza Surveillance and Response System (GISRS)"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0030","doi-asserted-by":"crossref","first-page":"6573","DOI":"10.1016\/j.vaccine.2021.08.010","article-title":"A research and development (R&D) roadmap for influenza vaccines: looking toward the future","volume":"39","author":"Moore","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0035","doi-asserted-by":"crossref","first-page":"933","DOI":"10.2169\/internalmedicine.3616-19","article-title":"Estimation of the effectiveness of quadrivalent influenza vaccines by distinguishing between influenza A (H1N1) pdm09 and influenza A (H3N2) using rapid influenza diagnostic tests during the 2018-2019 season","volume":"59","author":"Ando","year":"2020","journal-title":"Intern. Med."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0040","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.4049\/jimmunol.2001287","article-title":"Influenza Virus and SARS-CoV-2 Vaccines","volume":"206","author":"Sandor","year":"2021","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0045","doi-asserted-by":"crossref","first-page":"655","DOI":"10.7326\/M20-6976","article-title":"The proportion of SARS-CoV-2 infections that are asymptomatic","volume":"174","author":"Oran","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0050","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.chom.2021.06.016","article-title":"The success of SARS-CoV-2 vaccines and challenges ahead","volume":"29","author":"Subbarao","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0055","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.copbio.2021.09.016","article-title":"Principles for designing an optimal mRNA lipid nanoparticle vaccine","volume":"73","author":"Kon","year":"2022","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0060","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00031-14","article-title":"Characterization of a novel influenza virus in cattle and swine: proposal for a new genus in the Orthomyxoviridae family","volume":"5","author":"Hause","year":"2014","journal-title":"mBio"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0065","series-title":"Orhomyxoviruses","first-page":"649","author":"Howley","year":"2020"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0070","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003176","article-title":"Isolation of a novel swine influenza virus from Oklahoma in 2011 which is distantly related to human influenza C viruses","volume":"9","author":"Hause","year":"2013","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0075","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.3201\/eid2308.170059","article-title":"Influenza D virus in animal species in Guangdong Province, southern China","volume":"23","author":"Zhai","year":"2017","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0080","author":"WHO Influenza (Seasonal)"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0085","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1128\/JVI.02175-15","article-title":"Identification of a novel viral protein expressed from the PB2 segment of influenza A virus","volume":"90","author":"Yamayoshi","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0090","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1038\/304076a0","article-title":"Single amino acid substitutions in influenza haemagglutinin change receptor binding specificity","volume":"304","author":"Rogers","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0095","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/0042-6822(74)90276-1","article-title":"Characterization of temperature sensitive influenza virus mutants defective in neuraminidase","volume":"61","author":"Palese","year":"1974","journal-title":"Virology"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0100","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0092-8674(92)90452-I","article-title":"Influenza virus M2 protein has ion channel activity","volume":"69","author":"Pinto","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0105","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1073\/pnas.79.4.968","article-title":"Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion","volume":"79","author":"Skehel","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0168-1702(86)90004-3","article-title":"Spin-labeling of influenza virus hemagglutinin permits analysis of the conformational change at low pH and its inhibition by antibody","volume":"4","author":"Yoden","year":"1986","journal-title":"Virus Res."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0115","doi-asserted-by":"crossref","first-page":"8669","DOI":"10.1128\/JVI.79.13.8669-8674.2005","article-title":"In vitro assembly of PB2 with a PB1-PA dimer supports a new model of assembly of influenza a virus polymerase subunits into a functional trimeric complex","volume":"79","author":"Deng","year":"2005","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0120","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1128\/JVI.01533-09","article-title":"Nuclear import and assembly of influenza A virus RNA polymerase studied in live cells by fluorescence cross-correlation spectroscopy","volume":"84","author":"Huet","year":"2010","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0125","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.virol.2009.08.015","article-title":"Nuclear dynamics of influenza a virus ribonucleoproteins revealed by live-cell imaging studies","volume":"394","author":"Loucaides","year":"2009","journal-title":"Virology"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0130","doi-asserted-by":"crossref","first-page":"9144","DOI":"10.1128\/JVI.78.17.9144-9153.2004","article-title":"The PA subunit is required for efficient nuclear accumulation of the PB1 subunit of the influenza A virus RNA polymerase complex","volume":"78","author":"Fodor","year":"2004","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0135","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1038\/nature07745","article-title":"The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit","volume":"458","author":"Dias","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0140","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00528-17","article-title":"Influenza A virus NS1 protein promotes efficient nuclear export of unspliced viral M1 mRNA","volume":"91","author":"Pereira","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0145","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1099\/vir.0.069542-0","article-title":"Influenza virus non-structural protein NS1: interferon antagonism and beyond","volume":"95","author":"Marc","year":"2014","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0150","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1006\/viro.1993.1473","article-title":"Molecular assembly of influenza virus: association of the NS2 protein with virion matrix","volume":"196","author":"Yasuda","year":"1993","journal-title":"Virology"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0155","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/BF01322743","article-title":"Perpetuation of influenza a viruses in Alaskan waterfowl reservoirs","volume":"140","author":"Ito","year":"1995","journal-title":"Arch. Virol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0160","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1007\/s007050050681","article-title":"Precursor genes of future pandemic influenza viruses are perpetuated in ducks nesting in Siberia","volume":"145","author":"Okazaki","year":"2000","journal-title":"Arch. Virol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0165","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/0042-6822(78)90247-7","article-title":"Intestinal influenza: replication and characterization of influenza viruses in ducks","volume":"84","author":"Webster","year":"1978","journal-title":"Virology"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0170","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2307\/1592241","article-title":"Survey of the hemagglutinin (HA) cleavage site sequence of H5 and H7 avian influenza viruses: amino acid sequence at the HA cleavage site as a marker of pathogenicity potential","volume":"40","author":"Senne","year":"1996","journal-title":"Avian Dis."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0175","doi-asserted-by":"crossref","first-page":"6074","DOI":"10.1128\/jvi.68.9.6074-6078.1994","article-title":"Proprotein-processing endoproteases PC6 and furin both activate hemagglutinin of virulent avian influenza viruses","volume":"68","author":"Horimoto","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0180","doi-asserted-by":"crossref","first-page":"8018","DOI":"10.1128\/JVI.74.17.8018-8027.2000","article-title":"Targeted infection of endothelial cells by avian influenza virus A\/FPV\/Rostock\/34 (H7N1) in chicken embryos","volume":"74","author":"Feldmann","year":"2000","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0185","doi-asserted-by":"crossref","first-page":"7367","DOI":"10.1128\/JVI.72.9.7367-7373.1998","article-title":"Molecular basis for the generation in pigs of influenza a viruses with pandemic potential","volume":"72","author":"Ito","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0190","series-title":"Global Infelunza Strategy 2019-2030","author":"W. H. Organization","year":"2019"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0195","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1038\/nature08260","article-title":"In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses","volume":"460","author":"Itoh","year":"2009","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0200","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1093\/infdis\/jiv534","article-title":"Global mortality impact of the 1957-1959 influenza pandemic","volume":"213","author":"Viboud","year":"2016","journal-title":"J. Infect. Dis."},{"issue":"Pt 9","key":"10.1016\/j.jconrel.2022.01.046_bb0205","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1099\/0022-1317-75-9-2183","article-title":"Potential for transmission of avian influenza viruses to pigs","volume":"75","author":"Kida","year":"1994","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0210","author":"WHO Global Alert and Response (GAR)"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0215","author":"Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003\u2013-2021"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0220","author":"FAO H7N9 situation update"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0225","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fmicb.2018.00123","article-title":"Universal vaccines and vaccine platforms to protect against influenza viruses in humans and agriculture","volume":"9","author":"Raj\u00e3o","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0230","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/nm.4223","article-title":"Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain","volume":"22","author":"Raymond","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0235","doi-asserted-by":"crossref","first-page":"12578","DOI":"10.1073\/pnas.1712377114","article-title":"Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains","volume":"114","author":"Zost","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0240","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(17)30129-0","article-title":"Influenza","volume":"390","author":"Paules","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0245","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1002\/pro.5560031007","article-title":"Influenza virus neuraminidase: structure, antibodies, and inhibitors","volume":"3","author":"Colman","year":"1994","journal-title":"Protein Sci."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0250","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1002\/j.1460-2075.1985.tb04038.x","article-title":"The molecular basis of the specific anti-influenza action of amantadine","volume":"4","author":"Hay","year":"1985","journal-title":"EMBO J."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0255","article-title":"Adamantane-resistant influenza a viruses in the world (1902-2013): frequency and distribution of M2 gene mutations","volume":"10","author":"Dong","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0260","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/IDR.S105473","article-title":"Drug resistance in influenza A virus: the epidemiology and management","volume":"10","author":"Hussain","year":"2017","journal-title":"Infect Drug Resist."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0265","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/jama.283.8.1016","article-title":"Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group","volume":"283","author":"Treanor","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0270","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1086\/650458","article-title":"Effects of oseltamivir treatment on duration of clinical illness and viral shedding and household transmission of influenza virus","volume":"50","author":"Ng","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0275","doi-asserted-by":"crossref","first-page":"2633","DOI":"10.1056\/NEJMp058291","article-title":"Oseltamivir resistance--disabling our influenza defenses","volume":"353","author":"Moscona","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0280","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1126\/science.1187816","article-title":"Permissive secondary mutations enable the evolution of influenza oseltamivir resistance","volume":"328","author":"Bloom","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0285","series-title":"Influenza A(H1N1)Virus Resistance to Oseltamivir - 2008\/2009 Infleunza Season, Northern Hemisphere","author":"WHO","year":"2009"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0290","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jcv.2009.11.003","article-title":"Emergence of H274Y oseltamivir-resistant A(H1N1) influenza viruses in Japan during the 2008-2009 season","volume":"47","author":"Baranovich","year":"2010","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0295","doi-asserted-by":"crossref","first-page":"4929","DOI":"10.3390\/v7092850","article-title":"Clinical implications of antiviral resistance in influenza","volume":"7","author":"Li","year":"2015","journal-title":"Viruses"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0300","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.antiviral.2018.10.008","article-title":"In vitro characterization of baloxavir acid, a first-in-class cap-dependent endonuclease inhibitor of the influenza virus polymerase PA subunit","volume":"160","author":"Noshi","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0305","doi-asserted-by":"crossref","first-page":"9633","DOI":"10.1038\/s41598-018-27890-4","article-title":"Characterization of influenza virus variants induced by treatment with the endonuclease inhibitor baloxavir marboxil","volume":"8","author":"Omoto","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0310","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1038\/s41598-019-39683-4","article-title":"Inhibition of avian-origin influenza a(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil","volume":"9","author":"Taniguchi","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0315","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1128\/AAC.49.3.981-986.2005","article-title":"Mechanism of action of T-705 against influenza virus","volume":"49","author":"Furuta","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0320","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.antiviral.2013.09.015","article-title":"Favipiravir (T-705), a novel viral RNA polymerase inhibitor","volume":"100","author":"Furuta","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0325","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2183\/pjab.93.027","article-title":"Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase","volume":"93","author":"Furuta","year":"2017","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0330","doi-asserted-by":"crossref","first-page":"6668","DOI":"10.1021\/jm5007275","article-title":"Discovery of a novel, first-in-class, orally bioavailable azaindole inhibitor (VX-787) of influenza PB2","volume":"57","author":"Clark","year":"2014","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0335","first-page":"jiaa376","article-title":"A phase 2 study of pimodivir (JNJ-63623872) in combination with oseltamivir in elderly and nonelderly adults hospitalized with influenza A infection: OPAL study","author":"O\u2019Neil","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0340","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2020.582287","article-title":"The coronaviruses of animals and birds: their zoonosis, vaccines, and models for SARS-CoV and SARS-CoV2","volume":"7","author":"Alluwaimi","year":"2020","journal-title":"Front Vet. Sci."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0345","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(20)30557-2","article-title":"SARS-CoV-2 is an appropriate name for the new coronavirus","volume":"395","author":"Wu","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0350","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.7150\/ijbs.45472","article-title":"Zoonotic origins of human coronaviruses","volume":"16","author":"Ye","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0355","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: an overview of their replication and pathogenesis","volume":"1282","author":"Fehr","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0360","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/bs.aivir.2016.08.008","article-title":"The nonstructural proteins directing coronavirus RNA synthesis and processing","volume":"96","author":"Snijder","year":"2016","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0365","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1126\/science.abb7498","article-title":"Structure of the RNA-dependent RNA polymerase from COVID-19 virus","volume":"368","author":"Gao","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0370","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/jmv.25681","article-title":"Emerging coronaviruses: genome structure, replication, and pathogenesis","volume":"92","author":"Chen","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0375","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1128\/JVI.02596-14","article-title":"The nsp3 macrodomain promotes virulence in mice with coronavirus-induced encephalitis","volume":"89","author":"Fehr","year":"2015","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0380","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/S0022-2836(03)00865-9","article-title":"Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage","volume":"331","author":"Snijder","year":"2003","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0385","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0390","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41564-020-0688-y","article-title":"Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses","volume":"5","author":"Letko","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0395","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.576622","article-title":"The SARS-CoV-2 spike glycoprotein biosynthesis, structure, function, and antigenicity: implications for the design of spike-based vaccine immunogens","volume":"11","author":"Duan","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0400","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/bs.aivir.2019.08.002","article-title":"Structural insights into coronavirus entry","volume":"105","author":"Tortorici","year":"2019","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0405","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00754-20","article-title":"Nafamostat mesylate blocks activation of SARS-CoV-2: new treatment option for COVID-19","volume":"64","author":"Hoffmann","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0410","doi-asserted-by":"crossref","first-page":"11727","DOI":"10.1073\/pnas.2003138117","article-title":"Cell entry mechanisms of SARS-CoV-2","volume":"117","author":"Shang","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0415","doi-asserted-by":"crossref","first-page":"8801","DOI":"10.1128\/JVI.77.16.8801-8811.2003","article-title":"The coronavirus spike protein is a class I virus fusion protein: structural and functional characterization of the fusion core complex","volume":"77","author":"Bosch","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0420","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/cr.2008.15","article-title":"SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway","volume":"18","author":"Wang","year":"2008","journal-title":"Cell Res."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0425","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.molcel.2020.07.027","article-title":"Coronavirus RNA proofreading: molecular basis and therapeutic targeting","volume":"79","author":"Robson","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0430","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0065-3527(05)64006-7","article-title":"Molecular interactions in the assembly of coronaviruses","volume":"64","author":"de Haan","year":"2005","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0435","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.virol.2006.11.027","article-title":"The intracellular sites of early replication and budding of SARS-coronavirus","volume":"361","author":"Stertz","year":"2007","journal-title":"Virology"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0440","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1002\/pro.3909","article-title":"Architecture and self-assembly of the SARS-CoV-2 nucleocapsid protein","volume":"29","author":"Ye","year":"2020","journal-title":"Protein Sci."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0445","doi-asserted-by":"crossref","first-page":"14040","DOI":"10.1073\/pnas.0506735102","article-title":"Severe acute respiratory syndrome coronavirus-like virus in Chinese horseshoe bats","volume":"102","author":"Lau","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0450","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1126\/science.1118391","article-title":"Bats are natural reservoirs of SARS-like coronaviruses","volume":"310","author":"Li","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0455","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.3201\/eid1911.131172","article-title":"Middle East respiratory syndrome coronavirus in bats, Saudi Arabia","volume":"19","author":"Memish","year":"2013","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0460","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006698","article-title":"Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus","volume":"13","author":"Hu","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0465","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12250-015-3703-3","article-title":"Longitudinal surveillance of SARS-like coronaviruses in bats by quantitative real-time PCR","volume":"31","author":"Wang","year":"2016","journal-title":"Virol. Sin."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0470","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1401505","article-title":"Evidence for camel-to-human transmission of MERS coronavirus","volume":"370","author":"Azhar","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0475","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1126\/science.1087139","article-title":"Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China","volume":"302","author":"Guan","year":"2003","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0480","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1016\/j.cub.2020.09.030","article-title":"A novel bat coronavirus closely related to SARS-CoV-2 contains natural insertions at the S1\/S2 cleavage site of the spike protein","volume":"30","author":"Zhou","year":"2020","journal-title":"Curr. Biol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104742","article-title":"The spike glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent in CoV of the same clade","volume":"176","author":"Coutard","year":"2020","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0490","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.3201\/eid2607.200092","article-title":"Possible bat origin of severe acute respiratory syndrome coronavirus 2","volume":"26","author":"Lau","year":"2020","journal-title":"Emerg. Infect. Dis."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0495","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/s41586-020-2313-x","article-title":"Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins","volume":"583","author":"Xiao","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0500","series-title":"Bat Coronaviruses","author":"Ge","year":"2015"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0505","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1073\/pnas.0409608102","article-title":"Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human","volume":"102","author":"Song","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0510","doi-asserted-by":"crossref","first-page":"15748","DOI":"10.1073\/pnas.0403812101","article-title":"CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus","volume":"101","author":"Jeffers","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0515","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.2353\/ajpath.2007.061088","article-title":"Pathology and pathogenesis of severe acute respiratory syndrome","volume":"170","author":"Gu","year":"2007","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0520","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.virusres.2007.01.022","article-title":"Pathogenetic mechanisms of severe acute respiratory syndrome","volume":"133","author":"Guo","year":"2008","journal-title":"Virus Res."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0525","doi-asserted-by":"crossref","first-page":"11297","DOI":"10.1128\/JVI.01498-14","article-title":"Rooting the phylogenetic tree of middle East respiratory syndrome coronavirus by characterization of a conspecific virus from an African bat","volume":"88","author":"Corman","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0530","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00473-12","article-title":"Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans","volume":"3","author":"van Boheemen","year":"2012","journal-title":"mBio"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0535","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(15)60454-8","article-title":"Middle East respiratory syndrome","volume":"386","author":"Zumla","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0540","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nature12005","article-title":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC","volume":"495","author":"Raj","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0545","doi-asserted-by":"crossref","first-page":"9220","DOI":"10.1128\/JVI.00676-14","article-title":"Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4","volume":"88","author":"van Doremalen","year":"2014","journal-title":"J. Virol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0550","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ajpath.2015.09.014","article-title":"Dipeptidyl peptidase 4 distribution in the human respiratory tract: implications for the Middle East respiratory syndrome","volume":"186","author":"Meyerholz","year":"2016","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0555","doi-asserted-by":"crossref","first-page":"20662","DOI":"10.2807\/1560-7917.ES2013.18.50.20662","article-title":"Middle East respiratory syndrome coronavirus (MERS-CoV) serology in major livestock species in an affected region in Jordan, June to September 2013","volume":"18","author":"Reusken","year":"2013","journal-title":"Euro Surveill."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0560","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/tbed.12212","article-title":"Middle East respiratory syndrome coronavirus antibody reactors among camels in Dubai, United Arab Emirates, in 2005","volume":"61","author":"Alexandersen","year":"2014","journal-title":"Transbound. Emerg. Dis."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0565","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1056\/NEJMoa1306742","article-title":"Hospital outbreak of Middle East respiratory syndrome coronavirus","volume":"369","author":"Assiri","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0570","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1056\/NEJMoa1405858","article-title":"Transmission of MERS-coronavirus in household contacts","volume":"371","author":"Drosten","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0575","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/1469-0691.12562","article-title":"Screening for Middle East respiratory syndrome coronavirus infection in hospital patients and their healthcare worker and family contacts: a prospective descriptive study","volume":"20","author":"Memish","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0580","doi-asserted-by":"crossref","DOI":"10.1016\/j.envres.2020.109858","article-title":"Imiquimod - a toll like receptor 7 agonist - is an ideal option for management of COVID 19","volume":"188","author":"Angelopoulou","year":"2020","journal-title":"Environ. Res."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0585","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/sj.cdd.4401850","article-title":"TLR signaling","volume":"13","author":"Kawai","year":"2006","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0590","doi-asserted-by":"crossref","first-page":"3810","DOI":"10.1038\/s41467-020-17665-9","article-title":"Activation and evasion of type I interferon responses by SARS-CoV-2","volume":"11","author":"Lei","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0595","doi-asserted-by":"crossref","DOI":"10.3390\/cells10030530","article-title":"SARS-CoV-2 nucleocapsid protein targets RIG-I-like receptor pathways to inhibit the induction of interferon response","volume":"10","author":"Oh","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0600","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1126\/science.abc8665","article-title":"Structural basis for translational shutdown and immune evasion by the Nsp1 protein of SARS-CoV-2","volume":"369","author":"Thoms","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0605","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41392-020-00438-7","article-title":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) membrane (M) protein inhibits type I and III interferon production by targeting RIG-I\/MDA-5 signaling","volume":"5","author":"Zheng","year":"2020","journal-title":"Signal Transduct Target Ther."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0610","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41421-020-00208-3","article-title":"SARS-CoV-2 N protein antagonizes type I interferon signaling by suppressing phosphorylation and nuclear translocation of STAT1 and STAT2","volume":"6","author":"Mu","year":"2020","journal-title":"Cell Discov."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0615","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1002\/jmv.25819","article-title":"Neutrophil-to-lymphocyte ratio and lymphocyte-to-C-reactive protein ratio in patients with severe coronavirus disease 2019 (COVID-19): a meta-analysis","volume":"92","author":"Lagunas-Rangel","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0620","doi-asserted-by":"crossref","DOI":"10.1126\/science.abd4570","article-title":"Inborn errors of type I IFN immunity in patients with life-threatening COVID-19","volume":"370","author":"Zhang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0625","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.cytogfr.2020.06.001","article-title":"SARS-CoV-2 infection: the role of cytokines in COVID-19 disease","volume":"54","author":"Costela-Ruiz","year":"2020","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0630","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1038\/nrmicro3143","article-title":"A decade after SARS: strategies for controlling emerging coronaviruses","volume":"11","author":"Graham","year":"2013","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0635","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nm1726","article-title":"Engineering attenuated virus vaccines by controlling replication fidelity","volume":"14","author":"Vignuzzi","year":"2008","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0640","series-title":"Vaccines and Clinical Immunization","first-page":"695","author":"Mak","year":"2006"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0645","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1126\/science.1155761","article-title":"Virus attenuation by genome-scale changes in codon pair bias","volume":"320","author":"Coleman","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107586","article-title":"Mechanism of virus attenuation by codon pair deoptimization","volume":"31","author":"Groenke","year":"2020","journal-title":"Cell Rep."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0655","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/bs.aivir.2016.08.003","article-title":"Molecular basis of coronavirus virulence and vaccine development","volume":"96","author":"Enjuanes","year":"2016","journal-title":"Adv. Virus Res."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0660","series-title":"Chapter 1 - Biotechnologies for the Management of Genetic Resources for Food and Agricultur","first-page":"1","author":"Lidder","year":"2012"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0665","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173751","article-title":"COVID-19 vaccine: a recent update in pipeline vaccines, their design and development strategies","volume":"892","author":"Rawat","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0670","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1016\/j.vaccine.2007.01.106","article-title":"Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin","volume":"25","author":"Bright","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0675","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.antiviral.2017.11.007","article-title":"A virus-like particle of the hepatitis B virus preS antigen elicits robust neutralizing antibodies and T cell responses in mice","volume":"149","author":"Cai","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0680","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(04)17398-4","article-title":"Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial","volume":"364","author":"Harper","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0685","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12929-020-00695-2","article-title":"Coronavirus vaccine development: from SARS and MERS to COVID-19","volume":"27","author":"Li","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0690","doi-asserted-by":"crossref","DOI":"10.1371\/annotation\/2965cfae-b77d-4014-8b7b-236e01a35492","article-title":"Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus","volume":"7","author":"Tseng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0695","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.virol.2005.09.020","article-title":"Replication-defective viruses as vaccines and vaccine vectors","volume":"344","author":"Dudek","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0700","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1016\/j.copbio.2007.10.010","article-title":"Replicating and non-replicating viral vectors for vaccine development","volume":"18","author":"Robert-Guroff","year":"2007","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0705","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola ca Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0710","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41541-020-00221-3","article-title":"Evaluation of the immunogenicity of prime-boost vaccination with the replication-deficient viral vectored COVID-19 vaccine candidate ChAdOx1 nCoV-19","volume":"5","author":"Graham","year":"2020","journal-title":"NPJ Vacc."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0715","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1001\/jama.2021.3199","article-title":"SARS-CoV-2 Vaccines","volume":"325","author":"Creech","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0720","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","article-title":"SARS-CoV-2 vaccines in development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0725","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/s41591-021-01270-4","article-title":"Neutralization of SARS-CoV-2 spike 69\/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera","volume":"27","author":"Xie","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0730","doi-asserted-by":"crossref","first-page":"319","DOI":"10.4155\/tde-2016-0006","article-title":"mRNA vaccine delivery using lipid nanoparticles","volume":"7","author":"Reichmuth","year":"2016","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0735","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0140-6736(20)31022-9","article-title":"Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial","volume":"395","author":"Wang","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0740","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd1877","article-title":"Acyclic nucleoside phosphonates: a key class of antiviral drugs","volume":"4","author":"De Clercq","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0745","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1021\/acs.jpcb.0c04198","article-title":"Structural basis of the potential binding mechanism of remdesivir to SARS-CoV-2 RNA-dependent RNA polymerase","volume":"124","author":"Zhang","year":"2020","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0750","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"Spinner","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0755","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0760","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.ijbiomac.2021.10.144","article-title":"COVID-19: a review of newly formed viral clades, pathophysiology, therapeutic strategies and current vaccination tasks","volume":"193","author":"Murugan","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0765","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12985-020-01412-z","article-title":"Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis","volume":"17","author":"Shrestha","year":"2020","journal-title":"Virol. J."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0775","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112276","article-title":"Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19","volume":"144","author":"Malek","year":"2021","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0780","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.antiviral.2013.06.002","article-title":"Nuclear localization of dengue virus (DENV) 1-4 non-structural protein 5; protection against all 4 DENV serotypes by the inhibitor Ivermectin","volume":"99","author":"Tay","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0785","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1242\/jeb.118570","article-title":"Characterization of the target of ivermectin, the glutamate-gated chloride channel, from Anopheles gambiae","volume":"218","author":"Meyers","year":"2015","journal-title":"J. Exp. Biol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0790","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1042\/BJ20120150","article-title":"Ivermectin is a specific inhibitor of importin \u03b1\/\u03b2-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus","volume":"443","author":"Wagstaff","year":"2012","journal-title":"Biochem. J."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0795","first-page":"1","article-title":"Binding mechanism and structural insights into the identified protein target of COVID-19 and importin-alpha with in-vitro effective drug ivermectin","author":"Sen Gupta","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0800","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00011-008-8007-8","article-title":"Ivermectin inhibits LPS-induced production of inflammatory cytokines and improves LPS-induced survival in mice","volume":"57","author":"Zhang","year":"2008","journal-title":"Inflamm. Res."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0805","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0810","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1073\/pnas.92.7.2484","article-title":"ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans","volume":"92","author":"Kempf","year":"1995","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0815","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/135965350200600401","article-title":"Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience","volume":"6","author":"van Heeswijk","year":"2001","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0820","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0825","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1743-422X-2-69","article-title":"Chloroquine is a potent inhibitor of SARS coronavirus infection and spread","volume":"2","author":"Vincent","year":"2005","journal-title":"Virol. J."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0830","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1159\/000484955","article-title":"Chloroquine autophagic inhibition rebalances Th17\/Treg-mediated immunity and ameliorates systemic lupus erythematosus","volume":"44","author":"An","year":"2017","journal-title":"Cell. Physiol. Biochem."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0835","doi-asserted-by":"crossref","first-page":"4794","DOI":"10.4049\/jimmunol.1000702","article-title":"Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines","volume":"186","author":"Kuznik","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0840","first-page":"2436","article-title":"Immunosuppressive effects of hydroxychloroquine and artemisinin combination therapy via the nuclear factor-kappaB signaling pathway in lupus nephritis mice","volume":"15","author":"Liang","year":"2018","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0845","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s41232-020-00148-1","article-title":"Immunopathogenesis of SARS-CoV-2-induced pneumonia: lessons from influenza virus infection","volume":"40","author":"Miyazawa","year":"2020","journal-title":"Inflamm. Regen"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0850","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41573-019-0056-x","article-title":"Next-generation influenza vaccines: opportunities and challenges","volume":"19","author":"Wei","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0855","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.ejpb.2015.05.023","article-title":"Current and next generation influenza vaccines: formulation and production strategies","volume":"94","author":"Soema","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0860","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrmicro.2017.118","article-title":"The evolution of seasonal influenza viruses","volume":"16","author":"Petrova","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0865","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12929-020-0626-6","article-title":"Better influenza vaccines: an industry perspective","volume":"27","author":"Chen","year":"2020","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0870","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.virol.2021.02.005","article-title":"Updating the influenza virus library at Hokkaido University -It\u2019s potential for the use of pandemic vaccine strain candidates and diagnosis","volume":"557","author":"Nomura","year":"2021","journal-title":"Virology"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0875","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1056\/NEJMe2009758","article-title":"Asymptomatic transmission, the Achilles\u2019 Heel of current strategies to control Covid-19","volume":"382","author":"Gandhi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0880","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/s41577-021-00631-x","article-title":"The immunology of asymptomatic SARS-CoV-2 infection: what are the key questions?","volume":"21","author":"Boyton","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0885","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0890","doi-asserted-by":"crossref","first-page":"116","DOI":"10.20411\/pai.v6i1.441","article-title":"Antibody responses to SARS-CoV-2 mRNA vaccines are detectable in saliva","volume":"6","author":"Ketas","year":"2021","journal-title":"Pathog. Immun."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0895","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0900","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41579-021-00542-7","article-title":"Influenza virus and SARS-CoV-2: pathogenesis and host responses in the respiratory tract","volume":"19","author":"Flerlage","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0905","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1021\/acs.accounts.9b00368","article-title":"Lipid nanoparticle technology for clinical translation of siRNA therapeutics","volume":"52","author":"Kulkarni","year":"2019","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0910","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jconrel.2020.12.032","article-title":"The nanomedicine rush: new strategies for unmet medical needs based on innovative nano DDS","volume":"330","author":"Sato","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0915","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0920","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.4049\/jimmunol.147.9.2860","article-title":"Liposome-encapsulated antigens engender lysosomal processing for class II MHC presentation and cytosolic processing for class I presentation","volume":"147","author":"Harding","year":"1991","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0925","doi-asserted-by":"crossref","first-page":"987","DOI":"10.4155\/tde-2017-0071","article-title":"Integration of nano drug-delivery system with cancer immunotherapy","volume":"8","author":"Nakamura","year":"2017","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0930","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1038\/mt.2008.122","article-title":"Efficient MHC class I presentation by controlled intracellular trafficking of antigens in octaarginine-modified liposomes","volume":"16","author":"Nakamura","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0935","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ijpharm.2012.11.006","article-title":"Incorporation of polyinosine-polycytidylic acid enhances cytotoxic T cell activity and antitumor effects by octaarginine-modified liposomes encapsulating antigen, but not by octaarginine-modified antigen complex","volume":"441","author":"Nakamura","year":"2013","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0940","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jconrel.2012.05.010","article-title":"Targeting tumor antigens to dendritic cells using particulate carriers","volume":"161","author":"Joshi","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0945","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.jconrel.2013.07.004","article-title":"The nanoparticulation by octaarginine-modified liposome improves \u03b1-galactosylceramide-mediated antitumor therapy via systemic administration","volume":"171","author":"Nakamura","year":"2013","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0950","article-title":"Lipid nanoparticle acts as a potential adjuvant for influenza split vaccine without inducing inflammatory responses","volume":"8","author":"Shirai","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0955","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.jconrel.2014.04.004","article-title":"A new adjuvant delivery system \u2018cyclic di-GMP\/YSK05 liposome\u2019 for cancer immunotherapy","volume":"184","author":"Miyabe","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0960","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jconrel.2015.08.026","article-title":"Liposomes loaded with a STING pathway ligand, cyclic di-GMP, enhance cancer immunotherapy against metastatic melanoma","volume":"216","author":"Nakamura","year":"2015","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0965","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002852","article-title":"STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation","volume":"9","author":"Nakamura","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0970","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jconrel.2013.12.027","article-title":"Nanoparticulation of BCG-CWS for application to bladder cancer therapy","volume":"176","author":"Nakamura","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0975","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jconrel.2019.01.001","article-title":"Understanding structure-activity relationships of pH-sensitive cationic lipids facilitates the rational identification of promising lipid nanoparticles for delivering siRNAs in vivo","volume":"295","author":"Sato","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0980","doi-asserted-by":"crossref","first-page":"1807677","DOI":"10.1002\/adfm.201807677","article-title":"Lung-endothelium-targeted nanoparticles based on a pH-sensitive lipid and the GALA peptide enable robust gene silencing and the regression of metastatic lung cancer","volume":"29","author":"Abd Elwakil","year":"2019","journal-title":"Adv. Funct. Mater."},{"key":"10.1016\/j.jconrel.2022.01.046_bb0985","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1039\/D1MH00185J","article-title":"Engineered \u03b5-decalactone lipomers bypass the liver to selectively in vivo deliver mRNA to the lungs without targeting ligands","volume":"8","author":"Abd Elwakil","year":"2021","journal-title":"Mater. Horizon"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0990","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.jconrel.2016.01.042","article-title":"A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells","volume":"225","author":"Warashina","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.046_bb0995","doi-asserted-by":"crossref","first-page":"37849","DOI":"10.1038\/srep37849","article-title":"Small-sized, stable lipid nanoparticle for the efficient delivery of siRNA to human immune cell lines","volume":"6","author":"Nakamura","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1000","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1021\/acs.molpharmaceut.7b01166","article-title":"Reducing the cytotoxicity of lipid nanoparticles associated with a fusogenic cationic lipid in a natural killer cell line by introducing a polycation-based siRNA core","volume":"15","author":"Nakamura","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1005","doi-asserted-by":"crossref","first-page":"11335","DOI":"10.1038\/s41598-019-47799-w","article-title":"The silencing of indoleamine 2,3-dioxygenase 1 (IDO1) in dendritic cells by siRNA-loaded lipid nanoparticles enhances cell-based cancer immunotherapy","volume":"9","author":"Endo","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1010","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119652","article-title":"Lipid nanoparticles fuse with cell membranes of immune cells at low temperatures leading to the loss of transfection activity","volume":"587","author":"Nakamura","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.121140","article-title":"The hydrophobic tail of a pH-sensitive cationic lipid influences siRNA transfection activity and toxicity in human NK cell lines","volume":"609","author":"Nakamura","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1020","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev.bioeng.4.112601.125916","article-title":"Physics and applications of microfluidics in biology","volume":"4","author":"Beebe","year":"2002","journal-title":"Annu. Rev. Biomed. Eng."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1025","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.addr.2018.03.008","article-title":"Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems","volume":"128","author":"Maeki","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1030","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1021\/acs.molpharmaceut.9b01182","article-title":"The effect of size and charge of lipid nanoparticles prepared by microfluidic mixing on their lymph node transitivity and distribution","volume":"17","author":"Nakamura","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1035","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.addr.2020.06.003","article-title":"Dawn of lipid nanoparticles in lymph node targeting: potential in cancer immunotherapy","volume":"167","author":"Nakamura","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1040","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.chom.2021.05.004","article-title":"Innate immune and inflammatory responses to SARS-CoV-2: implications for COVID-19","volume":"29","author":"Lowery","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1045","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1050","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41586-021-03739-1","article-title":"Age-related immune response heterogeneity to SARS-CoV-2 vaccine BNT162b2","volume":"596","author":"Collier","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1055","article-title":"Central obesity, smoking habit, and hypertension are associated with lower antibody titres in response to COVID-19 mRNA vaccine","volume":"38","author":"Balena","year":"2021","journal-title":"Diabetes Metab. Res. Rev."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1060","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1016\/j.chom.2020.05.008","article-title":"Type I and type III interferons \u2013 induction, signaling, evasion, and application to combat COVID-19","volume":"27","author":"Park","year":"2020","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1065","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1070","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.chom.2016.01.007","article-title":"Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice","volume":"19","author":"Channappanavar","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1075","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1172\/JCI126363","article-title":"IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes","volume":"129","author":"Channappanavar","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1080","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1146\/annurev-immunol-032414-112240","article-title":"Innate immune pattern recognition: a cell biological perspective","volume":"33","author":"Brubaker","year":"2015","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1085","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/35099560","article-title":"Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3","volume":"413","author":"Alexopoulou","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1090","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1126\/science.1093616","article-title":"Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA","volume":"303","author":"Diebold","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1095","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/35047123","article-title":"A Toll-like receptor recognizes bacterial DNA","volume":"408","author":"Hemmi","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1100","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1146\/annurev-immunol-032713-120156","article-title":"Innate immune sensing and signaling of cytosolic nucleic acids","volume":"32","author":"Wu","year":"2014","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1105","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/nri3921","article-title":"STING: infection, inflammation and cancer","volume":"15","author":"Barber","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1110","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0264-410X(98)00439-3","article-title":"Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC","volume":"17","author":"Wong","year":"1999","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1115","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.4049\/jimmunol.1400840","article-title":"Stimulation of the RIG-I\/MAVS pathway by polyinosinic:polycytidylic acid upregulates IFN-\u03b2 in airway epithelial cells with minimal costimulation of IL-8","volume":"195","author":"Dauletbaev","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1120","doi-asserted-by":"crossref","DOI":"10.1016\/j.cej.2021.129392","article-title":"Inhalable nanovaccine with biomimetic coronavirus structure to trigger mucosal immunity of respiratory tract against COVID-19","volume":"418","author":"Zheng","year":"2021","journal-title":"Chem. Eng. J."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1125","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.3389\/fimmu.2020.01075","article-title":"Adjuvant effect of toll-like receptor 9 activation on cancer immunotherapy using checkpoint blockade","volume":"11","author":"Chuang","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1130","doi-asserted-by":"crossref","first-page":"3086","DOI":"10.1073\/pnas.1319268111","article-title":"Nonagonistic Dectin-1 ligand transforms CpG into a multitask nanoparticulate TLR9 agonist","volume":"111","author":"Kobiyama","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1135","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1089\/nat.2014.0509","article-title":"Liposome-encapsulated CpG enhances antitumor activity accompanying the changing of lymphocyte populations in tumor via intratumoral administration","volume":"25","author":"Kim","year":"2015","journal-title":"Nucl. Acid Ther."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1140","doi-asserted-by":"crossref","first-page":"48860","DOI":"10.18632\/oncotarget.10379","article-title":"Circulating nano-particulate TLR9 agonist scouts out tumor microenvironment to release immunogenic dead tumor cells","volume":"7","author":"Kitahata","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1145","article-title":"An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor-binding domain vaccine in aged mice","volume":"14","author":"Nanishi","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1150","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.immuni.2014.10.017","article-title":"STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors","volume":"41","author":"Woo","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1155","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13112695","article-title":"STING agonists as cancer therapeutics","volume":"13","author":"Amouzegar","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1160","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jconrel.2021.09.033","article-title":"Considerations for the delivery of STING ligands in cancer immunotherapy","volume":"339","author":"Petrovic","year":"2021","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1165","doi-asserted-by":"crossref","DOI":"10.1126\/science.aau0810","article-title":"Pulmonary surfactant-biomimetic nanoparticles potentiate heterosubtypic influenza immunity","volume":"367","author":"Wang","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1170","doi-asserted-by":"crossref","first-page":"103037","DOI":"10.1016\/j.isci.2021.103037","article-title":"Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2","volume":"24","author":"An","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1175","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41577-020-0307-4","article-title":"Clonal expansion of innate and adaptive lymphocytes","volume":"20","author":"Adams","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1180","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20201731","article-title":"Virus-specific NK cell memory","volume":"218","author":"Sheppard","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1185","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.coviro.2015.10.008","article-title":"Roles of natural killer cells in antiviral immunity","volume":"16","author":"Waggoner","year":"2016","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1190","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abd6832","article-title":"Natural killer cell immunotypes related to COVID-19 disease severity","volume":"5","author":"Maucourant","year":"2020","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1195","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108516","article-title":"COVID-19 pneumonia: CD8(+) T and NK cells are decreased in number but compensatory increased in cytotoxic potential","volume":"218","author":"Jiang","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1200","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1038\/s41586-021-04142-6","article-title":"Untimely TGF\u03b2 responses in COVID-19 limit antiviral functions of NK cells","volume":"600","author":"Witkowski","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1205","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1158\/2326-6066.CIR-17-0491","article-title":"Enhanced cancer immunotherapy with Smad3-silenced NK-92 cells","volume":"6","author":"Wang","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1210","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abk0172","article-title":"Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta)","volume":"7","author":"Trimpert","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1215","first-page":"1","article-title":"Mucosal vaccines \u2014 fortifying the frontiers","volume":"26","author":"Lavelle","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1220","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nmat2347","article-title":"Stealth particles give mucus the slip","volume":"8","author":"Cu","year":"2009","journal-title":"Nat. Mater."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1225","doi-asserted-by":"crossref","first-page":"431","DOI":"10.3389\/fimmu.2018.00431","article-title":"Lipid-based particles: versatile delivery systems for mucosal vaccination against infection","volume":"9","author":"Corth\u00e9sy","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1230","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jconrel.2015.11.006","article-title":"PEG modified liposomes containing CRX-601 adjuvant in combination with methylglycol chitosan enhance the murine sublingual immune response to influenza vaccination","volume":"223","author":"Oberoi","year":"2016","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1235","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1073\/pnas.0608611104","article-title":"Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus","volume":"104","author":"Lai","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1240","first-page":"6077","article-title":"Design and application of chitosan microspheres as oral and nasal vaccine carriers: an updated review","volume":"7","author":"Islam","year":"2012","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1245","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.ijpharm.2017.09.011","article-title":"Novel freeze-dried DDA and TPGS liposomes are suitable for nasal delivery of vaccine","volume":"533","author":"Yusuf","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139785","article-title":"Intranasal immunization with DOTAP cationic liposomes combined with DC-cholesterol induces potent antigen-specific mucosal and systemic immune responses in mice","volume":"10","author":"Tada","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1255","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/nri3727","article-title":"Dendritic cell-targeted vaccines \u2014 hope or hype?","volume":"14","author":"Kastenm\u00fcller","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1260","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/intimm\/dxu061","article-title":"A novel mucosal vaccine targeting Peyer\u2019s patch M cells induces protective antigen-specific IgA responses","volume":"26","author":"Shima","year":"2014","journal-title":"Int. Immunol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1265","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1016\/j.biomaterials.2013.11.073","article-title":"Targeted oral delivery of BmpB vaccine using porous PLGA microparticles coated with M cell homing peptide-coupled chitosan","volume":"35","author":"Jiang","year":"2014","journal-title":"Biomaterials"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1270","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1084\/jem.20070607","article-title":"A novel M cell-specific carbohydrate-targeted mucosal vaccine effectively induces antigen-specific immune responses","volume":"204","author":"Nochi","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1275","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/S0264-410X(00)00553-3","article-title":"Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants","volume":"19","author":"Pizza","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1280","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.1128\/IAI.66.9.4299-4304.1998","article-title":"Effectiveness of liposomes possessing surface-linked recombinant B subunit of cholera toxin as an oral antigen delivery system","volume":"66","author":"Harokopakis","year":"1998","journal-title":"Infect. Immun."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1285","doi-asserted-by":"crossref","first-page":"3342","DOI":"10.1016\/S0264-410X(02)00295-5","article-title":"Liposomal immunostimulatory DNA sequence (ISS-ODN): an efficient parenteral and mucosal adjuvant for influenza and hepatitis B vaccines","volume":"20","author":"Joseph","year":"2002","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1290","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3389\/fmicb.2013.00346","article-title":"Development of oligomannose-coated liposome-based nasal vaccine against human parainfluenza virus type 3","volume":"4","author":"Senchi","year":"2013","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1295","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.chom.2018.06.016","article-title":"Overcoming barriers in the path to a universal influenza virus vaccine","volume":"24","author":"Coughlan","year":"2018","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1300","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1016\/j.vaccine.2021.06.028","article-title":"The need for broadly protective COVID-19 vaccines: beyond S-only approaches","volume":"39","author":"Poland","year":"2021","journal-title":"Vaccine"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1305","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1126\/science.aac7263","article-title":"A stable trimeric influenza hemagglutinin stem as a broadly protective immunogen","volume":"349","author":"Impagliazzo","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1310","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nm.3927","article-title":"Hemagglutinin-stem nanoparticles generate heterosubtypic influenza protection","volume":"21","author":"Yassine","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1315","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/d41586-021-03672-3","article-title":"Omicron likely to weaken COVID vaccine protection","volume":"600","author":"Callaway","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1320","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1016\/j.immuni.2021.11.016","article-title":"Antigenic drift: understanding COVID-19","volume":"54","author":"Yewdell","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1325","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1330","doi-asserted-by":"crossref","first-page":"14179","DOI":"10.1038\/s41598-020-70864-8","article-title":"Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome","volume":"10","author":"Crooke","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1335","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1146\/annurev.immunol.22.012703.104538","article-title":"Cell biology of antigen processing in vitro and in vivo","volume":"23","author":"Trombetta","year":"2004","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1340","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.actbio.2021.06.023","article-title":"From influenza to COVID-19: lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases","volume":"131","author":"Pilkington","year":"2021","journal-title":"Acta Biomater."},{"key":"10.1016\/j.jconrel.2022.01.046_bb1345","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.cell.2014.04.054","article-title":"TLR signals induce phagosomal MHC-I delivery from the endosomal recycling compartment to allow cross-presentation","volume":"158","author":"Nair-Gupta","year":"2014","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2022.01.046_bb1350","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.immuni.2015.11.006","article-title":"Toll-like receptor 4 engagement on dendritic cells restrains phago-lysosome fusion and promotes cross-presentation of antigens","volume":"43","author":"Alloatti","year":"2015","journal-title":"Immunity"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922000682?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365922000682?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:24:20Z","timestamp":1759163060000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365922000682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":268,"alternative-id":["S0168365922000682"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.01.046","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Strategies for fighting pandemic virus infections: Integration of virology and drug delivery","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2022.01.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}